Skip to main content

Advanced Search

Advanced Search

Current Filters

Filter your query

Publication Types

Other

to

Newsletter Article

/

Verdict on Trump Drug Plan: a Tough Sale Ahead

The Trump administration faces a lengthy battle to make its plan to lower Medicare drug costs a reality, with resistance coming from its own party, Democrats, and large segments of the health care industry. Conservatives and the drug industry say it’s tantamount to government price controls and socialized medicine. Democrats are beating up the president for not going far enough, and doctors are worried their patients could lose access to critical medicines. Any rewards likely won’t materialize for years. (Sarah Karlin-Smith, Politico)

Publication Details

Date